All News

RheumNow Podcast square

The Late Edition (2.24.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
dental,periodontal

Periodontal Mucosal Breaks Trigger RA Disease Activity

d Jack Cush, MD

Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs).  RA activity has been linked to the severity of PD and mucosal inflammation.

Read Article
lumbar,spine,lbp,pain

Which Meds are Best for Acute Low Back Pain?

d EurekAlert!

Acute low back pain (LBP) is a common cause of disability. An analysis in the Journal of Orthopaedic Research examined which non-opioid drugs are best for treating this condition.

Read Article
cost.price_.biologic.injectable.jpg

New Drug Formulations – For Patients or Profits?

d Madelaine Feldman, MD

Wang et al., in a JAMA Network Research Letter, recently reviewed Medicaid expenditures on adalimumab (ADA), sold under the brand name HUMIRA®. They noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid between 2014 and 2021.

Read Article
Subscribe to the RheumNow podcast on your favorite podcast app to get automatic downloads of the latest content. Listen in the car, airplane, anywhere! Rate, review and subscribe! https://t.co/3EENe1VFKl https://t.co/V0X5BAtDBq

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparing ACR21 vs EULAR22 RA Guidelines https://t.co/sqYLrg9wC2 https://t.co/y3a8yDVQhP

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Arthralgia, Raynaud's & Anemia https://t.co/2H9EAZvP2s https://t.co/Bcerjoucjf

Links:

Dr. John Cush RheumNow ( View Tweet)
A Singular Case of Plural Effusion Shashank Suresh, MD, presents his poster at RWCS 2023. https://t.co/xAR2WcK9MN https://t.co/KVGM9ri3cj

Links:

Dr. John Cush RheumNow ( View Tweet)
Which Meds are Best for Acute Low Back Pain? Acute low back pain (LBP) is a common cause of disability. An analysis in the Journal of Orthopaedic Research examined which non-opioid drugs are best for treating this condition. https://t.co/StteWi87Y5 https://t.co/9CvYIqx5Cv

Links:

Dr. John Cush RheumNow ( View Tweet)
New Drug Formulations – For Patients or Profits? Wang et al in JAMA Network Research Letter, reviewed Medicaid expenditures on ADA, noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid from 2014-2021. https://t.co/W1sst12GJK https://t.co/OYLkSHEQ2X

Links:

Dr. John Cush RheumNow ( View Tweet)
32 men w/ B27+ #AS (Rx NSAIDs, BASDAI ~5.3) underwent exercise training (10d, 60min) w/ or w/o Pre-Rx w/ whole-body cryotherapy (WBC). WBC had significant drops in hsCRP, sP-Selectin, sVCAM-1, neopterin & signif decreases in BASDAI, BASFI, pain intensity https://t.co/8bmjTS4VOk https://t.co/ajrD8Z7C8v

Links:

Dr. John Cush RheumNow ( View Tweet)
Overview of Juvenile idiopathic arthritis (JIA) assoc uveitis (JIA-U) seen in 10–15% ofJIA pts, higher risk w/ ANA+, oligo-JIA, f& onset ≤6 yrs age. Rx options: topical steroids, MTX, ADA, INFLX, RTX and TCZ (review of TCZ in JIA-U) https://t.co/DIccOVLrmR https://t.co/6QD6g6orkp

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective study from a Taiwan health insurance claims data analysis looked at the association between Hashimoto's thyroiditis and lupus. https://t.co/159JNLY6tf https://t.co/JxR88a84MN

Links:

Dr. John Cush RheumNow ( View Tweet)
Chest Pain & Fever Lessons from the clinic, brought to you by https://t.co/4UQlqwujiR March 18 &19, 2023 - Dallas, TX https://t.co/k98wmxxG2k

Links:

Dr. John Cush RheumNow ( View Tweet)

Raynaud's Phenomenon: Now You See Me, Now You Don't Manmeet Kaur, MD, presents at RWCS 2023. https://t.co/VsRZmzycXH https://t.co/ysWaHABKoP

Links:

Dr. John Cush RheumNow ( View Tweet)
Heavy Metals and the Risk of Arthritis The etiology of arthritis was studied using US NHANES data and suggested that elevated concentrations of trace elements (TE: Pb, Cd, and Cu) were associated with increased risk of arthritis. https://t.co/z8bzOorqTz https://t.co/u5cQqXDId2

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a chance to listen to last week's podcast? Check out our sneak peek and see what Dr. Cush finds surprising. https://t.co/zQIyVWwA8k https://t.co/I3PEUGUx2L

Links:

Dr. John Cush RheumNow ( View Tweet)
Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars - majority say economics arent favorable to switch to biosimilar - Yet majority "very to somewhat” comfortable w/ biosimilars - US: Slow biosimilar uptake due to disappointing costs https://t.co/6dUR4gA3I5 https://t.co/2bLzE70h6y

Links:

Dr. John Cush RheumNow ( View Tweet)
Im not sure this was necessary but - a metanalysis of 10 RCTs w/ 847 OA patients shows colchicine use in osteoarthritis had no efficacy as far as pain reduction (vs control; SMD= 0.17) & no improvement in function (SMD, - 0.37) https://t.co/67d1ouJyQR https://t.co/6xBJcQCYZt

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 25 studies, betw 1985 - 2021, showed US average annual visits for RA=5.25 for US rheums (vs 3.3 ex-US) & 4.8 US non-rheums. SLE=3.24 & 12.3 for US non-Rheums. FM=1.8 for US rheums & 0.4 vs ex-US Rheums. Rheum Visits Decreased 1982 to 2019 https://t.co/5ugk34MJ3b https://t.co/NDMYZT7pil

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×